Home › Encyclopedia › Larazotide: Research Status and Trial Data
Research / Unapproved

Larazotide: Research Status and Trial Data

Molecular formulaC32H55N9O10
Molecular weight725.8 g/mol
Registered trials29
PubChem CID9810532

What larazotide is

Larazotide is an investigational compound with no approved drug label in the data reviewed. It has not received regulatory approval for any indication, and its status here is unapproved research. Chemically, larazotide is a peptide with the molecular formula C32H55N9O10 and a molecular weight of approximately 725.8 g/mol, catalogued under PubChem CID 9810532.

Trial footprint

Across registered studies, 29 clinical trials reference this compound area. The sample of associated trials in this dataset centers on migalastat, evaluated in Fabry disease research: a completed Phase 2 drug-drug interaction study with agalsidase, an active Phase 3 study in Fabry subjects with an amenable GLA variant and renal disease, and a completed Phase 1 safety study in healthy volunteers. These trials illustrate the type of clinical research activity found in the registry rather than any established finding for larazotide specifically.

FAQ

Is larazotide FDA approved?
No. Larazotide is classified as an unapproved research compound with no approved drug label identified in this dataset. It has not been evaluated or authorized by regulators for any medical use.
What is larazotide chemically?
Larazotide is a peptide compound with the molecular formula C32H55N9O10 and a molecular weight of about 725.8 g/mol. It is catalogued in PubChem under CID 9810532.
How many clinical trials involve larazotide?
The dataset reports 29 registered clinical trials associated with this compound area. Sample trials in the data focus on migalastat research in Fabry disease, spanning Phase 1 through Phase 3 designs.
Does the data show side effects for larazotide?
No adverse event report data was available in this dataset for larazotide. This means no side effect summary can be provided based on the information reviewed.
What conditions has larazotide been studied for?
The trial sample provided relates to migalastat studies in Fabry disease, including drug interaction, renal disease, and safety trials. This dataset does not confirm any specific approved or intended indication for larazotide itself.
This page is an editorial information resource. It does not sell, prescribe, or recommend any medication. Content is editorial information, not medical advice. Talk to your doctor before any treatment decision.

Sources: PubChem ClinicalTrials.gov

Updated 2026-09-19